Aurobindo Pharma on November 30 said its subsidiary has received approval from the U.S. health regulator to market a generic medication to treat asthma in children.
Eugia Pharma Specialities, a wholly-owned subsidiary of the company, has received final approval from the U.S. Food & Drug Administration (USFDA) to manufacture and market Budesonide Inhalation Suspension, the Hyderabad-based drug firm said in a regulatory filing.
The company's product is therapeutically equivalent to AstraZeneca Pharmaceuticals LP's Pulmicort Repsules Inhalation Suspension, it added.